Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi study shows extended Lovenox regimen reduces VTE risk
Sanofi says that the study showed the benefit of extended prophylaxis in acutely ill medical patients with reduced mobility by demonstrating the superiority of a five week course
Sanofi says that the study showed the benefit of extended prophylaxis in acutely ill medical patients with reduced mobility by demonstrating the superiority of a five week course
The alliance will initially cover four therapeutic areas: oncology, respiratory diseases, metabolic diseases and certain liver diseases. Alnylam and Roche also will collaborate on RNAi drug discovery for
According to the oncology company, the study also confirms previous observations that nimotuzumab inhibits ligand-dependent EGF receptor downstream signaling. “The data presented at SBNet provides further evidence that
The three-year collaboration is designed to discover and develop proprietary siRNA molecules against up to five specific targets provided by AstraZeneca. Under terms of the agreement, Silence Therapeutics
Tibotec Pharmaceuticals, a division of Johnson & Johnson, manufactures the drugs which are called etravirine (TMC125) and darunavir (TMC114). The studies examined the use of TMC125 in combination
The warning informed doctors that cases of fatal reactions in the lungs and kidneys in both term and premature babies had been found when the drug was administered
Under the agreement, Granules will develop and register selected products for US ANDA submission, and will receive up front and milestone payments. Heritage will retain exclusive sales and
The team, led by Karl Deisseroth, assistant professor of bioengineering and of psychiatry and behavioral sciences, found that in rats the differing mechanisms of depression and its treatment
Currently, Seasonale is marketed in the US where it was launched in October 2003 by Barr Laboratories’ subsidiary, Duramed Pharmaceuticals. In October 2005 Duramed granted Paladin an exclusive
Roche is filing a formal complaint against the US firm’s “poison-pill” defense provision to issue new shares at half price to its shareholders if Roche buys 20% of